Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
暂无分享,去创建一个
Edward S. Kim | S. Lippman | F. Khuri | W. Hong | J. Lee | V. Papadimitrakopoulou | Jack W. Martin | Lei Feng | W. William | D. Shin | Margaret Thomas | Lei Feng | J. Lee | W. Hong | William N. William | W. K. Hong | Edward S. Kim | J. J. Lee | Jack W. Martin | Dong M. Shin | W. William
[1] J S Lee,et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. , 1995, The New England journal of medicine.
[2] Edward S. Kim,et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. , 2006, Journal of the National Cancer Institute.
[3] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[4] J. Bartko,et al. Proving the null hypothesis. , 1991 .
[5] H. Stich,et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta‐carotene and with beta‐carotene plus vitamin A , 1988, International journal of cancer.
[6] W. Hong,et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. , 1986, The New England journal of medicine.
[7] R. Weber,et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. , 1993, The New England journal of medicine.
[8] W. Blackwelder,et al. Sample size graphs for "proving the null hypothesis". , 1984, Controlled clinical trials.
[9] L F Burmeister,et al. Proving the Null Hypothesis , 1992, Infection Control & Hospital Epidemiology.
[10] P. Balaram,et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. , 1997, Oral oncology.
[11] S. Lippman,et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. , 1997, Journal of the National Cancer Institute.
[12] S. Lippman,et al. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. , 2006, Cancer research.
[13] S. Lippman,et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.
[14] G. Omenn,et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.
[15] D. Albanes,et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.
[16] M. Gorsky,et al. Oral leukoplakia and malignant transformation. A follow‐up study of 257 patients , 1984, Cancer.
[17] W C Blackwelder,et al. "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.
[18] M. Nair,et al. Response of oral leukoplakias to the administration of vitamin A. , 1988, Cancer letters.
[19] R. Makuch,et al. Sample size requirements for evaluating a conservative therapy. , 1978, Cancer treatment reports.
[20] S. Lippman,et al. Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] S. Lippman,et al. The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention , 2007, Clinical Cancer Research.